In parallel, phase separation inhibitors and designer peptides targeting low-complexity domains disrupt the abnormal aggregation of key ALS proteins such as FUS and TDP-43 [129,130]. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.